Letter Agreement, dated August 30, 2022, by and among the Company, Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals (Hong Kong) Co., Limited and Sichuan Clover Biopharmaceuticals, Inc
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
Exhibit 10.2
LETTER AGREEMENT
This Letter Agreement (the “Letter Agreement”), is entered into by and among Dynavax Technologies Corporation (“Dynavax”) and the undersigned counterparties (such counterparties collectively referred to as “Clover”) (each a “Party” and collectively, the “Parties”) effective as of the date of last signature below (the "Effective Date").
WHEREAS the Parties entered into that certain Supply Agreement dated 29 June 2021, as amended and supplemented to date, (the “Supply Agreement”);
WHEREAS, the Supply Agreement provides certain terms governing, among other things, initial binding commitments for orders for Dynavax CpG 1018 adjuvant, capacity for Dynavax to accept future purchase orders from Clover, volume-based pricing, the binding nature and/or cancelability of certain purchase orders issued by Clover from time to time and other terms and conditions relating thereto;
WHEREAS, Clover submitted, among others, purchase order numbered [*] (“PO [*]”) covering [*] kilograms of CpG 1018 adjuvant and Dynavax accepted the order;
WHEREAS, following submission of the PO [*], and pursuant to the terms of the Supply Agreement and the PO [*], the PO [*] became non-cancelable by Clover;
WHEREAS, Clover submitted and Dynavax accepted purchase order numbered [*] (“PO [*]”) with prescribed delivery dates and quantities;
WHEREAS, Clover desires to shift delivery dates for deliveries of portions of PO [*];
WHEREAS, in the course of its performance in compliance with the Supply Agreement and the PO [*], Dynavax incurred certain non-cancelable costs totaling $24,077,867 (the “Cancellation Fees”), as described in detail below, in connection with otherwise non-cancellable portions of the order;
WHEREAS, notwithstanding the non-cancelable nature of the order and the starting costs incurred by Dynavax, Clover now desires to cancel its obligations with respect to [*] kilograms (the “Cancelled Portion”) from PO [*];
WHEREAS, in connection with PO [*], Clover made the required pre-payment of the requisite percentage of the order value, representing $53,425,000 (the “Prepayment”) applicable to the Cancelled Portion; and
WHEREAS, the Parties now desire to make a one-time good faith modification to the above referenced orders, and certain other changes as described in greater detail below.
NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
|
| Invoices | Prepayment |
Prepayment (Cash) |
|
| $53,425,000 |
Cancellation Fees Incurred by Dynavax in connection with Cancelled Portion |
| $24,077,867 |
|
Credit Memo for cancelled [*] kg CpG 1018 to offset portion of original prepayment |
| (24,077,867) | (24,077,867) |
Remaining Prepayment as Available Credit |
| $0 | $29,347,133 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
| Original PO | Version 2 | Version 3 | |||
PO | Order Quantity (kg) | Delivery Date | Order Quantity (kg) | Delivery Date | Order Quantity (kg) | Delivery Date |
[*] | [*] | [*] | [*] | [*] | [*] | [*] |
[*] | [*] | [*] | [*] | |||
[*] | [*] | |||||
[*] | [*] | [*] | [*] | [*] | [*] | [*] |
[*] | [*] | [*] | [*] | |||
[*] | [*] | [*] | [*] | |||
[*] | [*] | [*] | [*] | |||
[*] | [*] | [*] | [*] | |||
[*] | [*] | [*] | [*] | |||
[*] | [*] | [*] | [*] | [*] | [*] | [*] |
[*] | [*] | [*] | [*] | [*] | [*] | [*] |
[*] | [*] | [*] | [*] | [*] | [*] |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
[Signature Pages Follow]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
Signed for and on behalf of Dynavax Technologies Corporation by:
By: /s/ David Novack
Title: President and COO
Date: 8/30/2022 | Signed for and on behalf of Zhejiang Clover Biopharmaceuticals, Inc.:
By: /s/ Joshua LIANG
Title: CEO, Board Director
Date: 2022.8.26
Signed for and on behalf of Clover Biopharmaceuticals (Hong Kong) Co., Limited:
By: /s/ Joshua LIANG
Title: CEO, Board Director
Date: 2022.8.26
Solely for purposes of Article 5 and Sections 3.2, 3.3 and 17.7 of Annex B of the Supply Agreement, signed for and on behalf of Sichuan Clover Biopharmaceuticals, Inc.:
By: /s/ Joshua LIANG
Title: CEO, Board Director
Date: 2022.8.26 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
Exhibit A – Detailed Breakdown by Month
Reconciling Deliveries with Costs and Invoice Due Dates
[*]
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.